SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over potential sales impact. Traders disagree on whether Inovios treatment could challenge Precigens position or whether PAPZIMEOSs established commercial lead and full approval offer an advantage over the rivals accelerated approval and commercialization hurdles.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, supported by strong refining performance, are driving attention. Traders are reacting positively to the earnings beat and heavy call activity, while some question whether unusually strong refining margins can last.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 results and stronger-than-expected Q4 profit outlook are driving attention, with traders emphasizing subscriber growth, improving margins, and better ad trends despite revenue and EPS misses. The sharp rise has surprised skeptics, while bulls argue the forward guidance matters more than the quarters headline results.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00385003 USD and is up 3.25 over the last 24 hours. It is currently trading on 374 active market(s) with $20,884,591.23 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

Jasmys announced AppBank collaboration and planned Money Twin personal-AI service are drawing attention alongside a burst of trading activity. Bulls see the partnership and JasmyChain as steps toward real utility, while skeptics argue that adoption and resulting demand for JASMY remain unproven; discussion also centers on volatile price moves and dip buying.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results beat expectations, with strong theme-park performance and improving streaming profitability driving a broadly constructive reaction and renewed analyst optimism. Some traders remain skeptical, pointing to the stocks long-running sluggishness and questioning whether the results can support a sustained re-rating.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

A sharp LINK rebound and surge in trading activity have fueled breakout talk, with traders debating whether momentum can continue or the move will fade into another pullback. Bullish holders point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption translates into value for the token and warn of continued volatility.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,174,495.43496562. The last known price of Ethereum is 2,241.26797415 USD and is down -0.51 over the last 24 hours. It is currently trading on 14214 active market(s) with $20,040,937,711.35 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

The reported record Binance hack is driving concern about crypto exchange security and possible selling pressure across the market, including Ethereum. Traders are split between expecting further downside as confidence and risk appetite weaken and viewing ETHs relative resilience and dip buying as signs the shock may be contained.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is drawing attention as South Korean equities sell off amid an unwind in crowded AI and memory-chip trades, with Samsung and SK Hynix weakness and leveraged positions amplifying volatility. Traders are split between expecting further forced selling and viewing the pullback as a potential buying opportunity.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios Q3 results beat expectations and full-year guidance rose, but shares sold off sharply after its Q4 outlook signaled slower organic growth and messaging deceleration. Traders are debating whether the strong results and potential AI-related demand offset the weaker near-term outlook; many view guidance as the main driver of the drop.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume rally has driven attention to AMP, with traders celebrating a possible technical breakout and speculating that renewed interest in Anvil, Flexa and stablecoin payments could support the tokens longer-term case. Others say the move lacks a clear confirmed catalyst and may fade like previous pumps.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)

The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround 

MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose 

Equity

MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday. 


MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.read more...

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (MapLight or the Company) (NASDAQ: MPLT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Futures Jump As Brent Tumbles Below $90 On Fresh Round Of Iran Ceasefire Optimism

Futures Jump As Brent Tumbles Below $90 On Fresh Round Of Iran Ceasefire Optimism

 A sharp drop in oil prices prompted by a quieter weekend for geopolitics and a pause in?MidEast hostilities also sparked a drop in bond yields and the USD. A?powerful relief rally in stocks and bonds...

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout...

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents

MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.read more...

Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by HC Wainwright

HC Wainwright raised shares of Maplight Therapeutics to a "strong-buy" rating in a research report on Monday...

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5% - Here's What Happened

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5% - Here's What Happened...

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

MapLight Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The twice-daily version of the drug met the study’s main goal, but not the once-daily version.</li><li>MapLight plans to meet with the U.S. Food and Drug Administration soon to discuss a confirmatory late-stage trial in schizophrenia.&nbsp;</li><li>Company leaders also said that the twice-daily results strengthen the case for an ongoing study of the same twice-daily dose in Alzheimer’s disease-related psychosis.</li></ul>Shares of MapLight Therapeutics (MPLT) closed 73% lower on Monday after the biotech reported mixed results from a mid-stage trial of its experimental schizophrenia drug.The drop erased more than $1 billion in market value, leaving the company’s valuation around $449 million after the selloff.<h2 class="st-heading-2">Mixed Results From Key Schizophrenia Trial</h2>MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms. Patients received either a placebo, a twice-daily dose, or a once-daily dose for five weeks.The twice-daily version met the study’s main goal. It produced a clear, statistically meaningful drop in overall symptom scores on the Positive and Negative Syndrome Scale (PANSS), a standard measure of schizophrenia symptom severity, compared with placebo.Patients who finished the full five weeks saw an even stronger benefit. The same dose showed a solid gain in thinking and memory skills among those who started with cognitive problems, the company said. That cognitive improvement appeared separate from the reduction in psychotic symptoms.The once-daily version showed some numerical gains and hit statistical significance on a few secondary measures, such as overall severity ratings and certain positive symptom scores. However, it fell short of statistical significance on the primary PANSS endpoint, disappointing investors.On the safety side, both doses were generally well tolerated, MapLight said. Dropout rates stayed manageable, with no major signals of movement problems, metabolic issues, or other serious burdens common with many older schizophrenia medicines.MapLight plans to meet with the U.S. Food and Drug Administration soon to discuss a confirmatory late-stage trial in schizophrenia focused on the successful twice-daily regimen, while also exploring optimized once-daily possibilities.Company leaders also said that the twice-daily results bolster the case for an ongoing study of the same twice-daily dose in Alzheimer’s disease-related psychosis, with results expected in the second half of 2027.<h2 class="st-heading-2">How Did MPLT Retail Traders React?</h2>On Stocktwits, retail sentiment around MPLT jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the selloff is a good opportunity to buy the stock, highlighting the company’s balance sheet. MapLight Therapeutics’ cash, cash equivalents, and investments totaled $395.2 million as of March 31.<stembedurl>https://www.stocktwits.com/ccledez/message/660138747</stembedurl>Another termed the selloff an overreaction.<stembedurl>https://www.stocktwits.com/Gunnar1/message/660084590</stembedurl>A third user commended the trial result as a “strong positive” and not a “disappointment disguised as success.”“A clinically and strategically important win, with especially encouraging cognition and tolerability—but not an efficacy blowout. ML-007C-MA has now moved from a sophisticated improvement hypothesis built on Cobenfy to a clinically validated potential second-generation muscarinic drug,” they said.<stembedurl>https://www.stocktwits.com/DistributionEquity/message/660080258</stembedurl><a href="https://stocktwits.com/symbol/MPLT">MPLT stock</a> has dropped 44% year to date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/asml-stock-tumbles-6-as-investors-weigh-china-risk-but-wall-street-and-retail-investors-dismiss-selloff/cZZxMRFR76t">ASML Stock Tumbles 6% As Investors Weigh China Risk — But Wall Street And Retail Investors Dismiss Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.58
Prev Close	$7.72
Open	$7.70
Dividend Yield	0.00%
50-Day Moving Average	$10.45
Beta	1.44
Avg. Volume	553,577.33
PE Ratio	-1.48

52-Week High	$40.43
52-Week Low	$7.44
Market Capitalization	$421.26M
EPS (Annual)	-$3.66
Price to Book	0.99
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MPLT Fundamentals